1. A 33-year-old man presents with fatigue, low libido, and erectile difficulties. Two fasting morning total testosterone levels are 210 and 235 ng/dL. His LH and FSH are low-normal, prolactin is normal, and an MRI of the pituitary is unremarkable. He and his wife have been trying to conceive for 8 months. Semen analysis shows a low-normal sperm concentration. Which of the following is the most appropriate management?
A) Begin transdermal testosterone gel now to relieve his symptoms, and reassure him that fertility will be unaffected because gels preserve spermatogenesis.
B) Begin biweekly intramuscular testosterone enanthate and bank sperm only if azoospermia develops after a year of therapy.
C) Avoid exogenous testosterone and instead initiate clomiphene citrate (a selective estrogen receptor modulator) or human chorionic gonadotropin to raise endogenous testosterone while preserving spermatogenesis, since he is actively attempting conception.
D) Start testosterone undecanoate orally with a high-fat meal, as oral formulations do not suppress the hypothalamic-pituitary-gonadal axis.
E) Initiate a GnRH agonist to stimulate the pituitary and raise both testosterone and sperm production.
ANSWER: C
Rationale:
Option C is correct. This man has symptomatic hypogonadism with low-normal gonadotropins (a secondary or mixed picture) and is actively trying to conceive with marginal sperm parameters. Exogenous testosterone of any formulation suppresses the hypothalamic-pituitary-gonadal axis, lowering LH and FSH and collapsing intratesticular testosterone, which suppresses spermatogenesis and commonly produces oligospermia or azoospermia. The appropriate strategy in a man who wants to preserve fertility is to raise endogenous testosterone without suppressing the axis: clomiphene citrate blocks hypothalamic estrogen receptor feedback to increase endogenous LH and FSH, and human chorionic gonadotropin acts as an LH-receptor agonist to maintain intratesticular testosterone — both raise testosterone while preserving spermatogenesis.
Option A: Option A is incorrect; transdermal testosterone gel suppresses spermatogenesis just as other testosterone formulations do, so the reassurance is false.
Option B: Option B is incorrect; starting an injectable testosterone ester now would suppress spermatogenesis during the very period he is trying to conceive, and deferring action until azoospermia develops is inappropriate.
Option D: Option D is incorrect; oral testosterone undecanoate, despite its lymphatic absorption route, still delivers systemic testosterone that suppresses the HPG axis and impairs spermatogenesis.
Option E: Option E is incorrect; a GnRH agonist initially causes a testosterone flare and then downregulates the pituitary, ultimately suppressing gonadotropins and testosterone — it is used for androgen deprivation, not for raising testosterone or preserving fertility.
2. A 55-year-old man on testosterone cypionate 200 mg intramuscularly every 2 weeks for hypogonadism returns for routine follow-up. He feels well but mentions intermittent headaches and facial flushing. His hematocrit is 57% (baseline before therapy was 45%). Which of the following is the most appropriate next step?
A) Reduce the testosterone dose or switch to a transdermal formulation, and consider therapeutic phlebotomy, because the hematocrit exceeds the 54% action threshold and the rising red cell mass increases blood viscosity and thrombotic risk.
B) Continue the current regimen unchanged and recheck the hematocrit in 1 year, since erythrocytosis on testosterone is expected and benign.
C) Permanently discontinue all testosterone therapy and decline to offer any future androgen treatment because the hematocrit elevation is an absolute lifelong contraindication.
D) Add low-dose aspirin and maintain the current testosterone dose, since antiplatelet therapy fully offsets the thrombotic risk of erythrocytosis.
E) Order an urgent bone marrow biopsy to evaluate for polycythemia vera before making any change to the testosterone regimen.
ANSWER: A
Rationale:
Option A is correct. Erythrocytosis is the most common dose-dependent adverse effect of testosterone replacement therapy, particularly with injectable esters that produce supraphysiological peaks. The established action threshold is a hematocrit above 54% (hemoglobin above ~18.5 g/dL); above this level, increased whole-blood viscosity raises the risk of venous and arterial thrombotic events. This patient's hematocrit of 57%, with symptoms suggesting hyperviscosity (headache, flushing), exceeds the threshold and warrants intervention: reduce the testosterone dose, switch to a transdermal preparation (which produces lower, steadier levels and less erythrocytosis), and/or perform therapeutic phlebotomy.
Option B: Option B is incorrect; a hematocrit above 54% with hyperviscosity symptoms requires action, not a year of observation.
Option C: Option C is incorrect; erythrocytosis is a manageable, dose-related effect, not an absolute lifelong contraindication; therapy can usually be continued after adjustment.
Option D: Option D is incorrect; antiplatelet therapy does not address the hyperviscosity that drives the thrombotic risk and does not substitute for dose reduction or phlebotomy.
Option E: Option E is incorrect; in a man with a clear cause of secondary erythrocytosis (injectable testosterone) and a baseline hematocrit that was normal, an urgent bone marrow biopsy is not indicated before adjusting the obvious driver; if needed, serum erythropoietin would be a reasonable noninvasive test, but immediate biopsy is excessive.
3. A 66-year-old man has taken finasteride 5 mg daily for benign prostatic hyperplasia for 3 years. After starting therapy, his PSA fell from 3.0 to 1.4 ng/mL and remained stable. Over the past 8 months, despite confirmed adherence, his PSA has risen steadily to 2.9 ng/mL. His digital rectal examination is unremarkable. Which of the following is the most appropriate interpretation and next step?
A) The rise is expected aging-related prostate growth; reassure the patient and continue routine annual screening without further evaluation, since the value remains below 4 ng/mL.
B) Double the finasteride dose to re-suppress the PSA, since the rise indicates the current dose is no longer adequately reducing DHT.
C) Stop finasteride because the PSA rise indicates the drug has caused prostatic inflammation; no oncologic evaluation is needed.
D) Recognize that a sustained rise in PSA during continued finasteride therapy is abnormal and concerning for prostate cancer — because finasteride's ongoing DHT suppression should keep PSA low — and refer for urologic evaluation regardless of the absolute value.
E) Conclude that PSA is uninterpretable on finasteride and discontinue PSA monitoring entirely going forward.
ANSWER: D
Rationale:
Option D is correct. Finasteride reduces PSA by approximately 50% within the first 3 to 6 months and then stabilizes it at a lower baseline. Once stable, the drug's ongoing DHT suppression should keep PSA low; therefore, a sustained upward trend in PSA during continued, adherent finasteride therapy is abnormal and is a recognized warning sign for prostate cancer. This patient's PSA has roughly doubled over 8 months on stable therapy, which warrants urologic evaluation regardless of whether the absolute value remains below a nominal threshold such as 4 ng/mL. (For interpreting absolute values, the measured PSA is doubled to estimate the untreated equivalent — here ~5.8 ng/mL — which further supports evaluation.)
Option A: Option A is incorrect; a rising PSA on finasteride is not benign aging-related growth, and a reassurance based solely on staying under 4 ng/mL ignores the suppressive pharmacodynamics that should keep the value low.
Option B: Option B is incorrect; finasteride does not "wear off" in an adherent patient, and increasing the dose to mask a rising PSA would be dangerous and could delay a cancer diagnosis.
Option C: Option C is incorrect; the PSA rise is not explained by drug-induced inflammation, and forgoing oncologic evaluation would be unsafe.
Option E: Option E is incorrect; PSA remains interpretable and clinically valuable on finasteride when correction and trend principles are applied; monitoring should continue, not be abandoned.
4. A 70-year-old man with newly diagnosed metastatic prostate cancer involving multiple thoracic vertebrae is scheduled to begin androgen deprivation therapy with the GnRH agonist leuprolide. He has mild back pain but no neurologic deficit. Which of the following is the most appropriate approach to initiating therapy?
A) Administer leuprolide alone; no additional medication is needed because GnRH agonists produce immediate testosterone suppression without any initial surge.
B) Start a non-steroidal androgen receptor antagonist such as bicalutamide before and during the first few weeks of leuprolide therapy to protect against the testosterone flare, which could otherwise stimulate tumor growth and precipitate spinal cord compression in a patient with vertebral metastases.
C) Administer leuprolide alone but pretreat with a high-dose corticosteroid, since the flare is caused by adrenal androgen release that responds to steroid suppression.
D) Delay all therapy for 6 weeks and treat only with analgesics, since starting androgen deprivation during active bone metastasis is contraindicated.
E) Begin testosterone supplementation alongside leuprolide to stabilize hormone levels during the transition to castrate testosterone.
ANSWER: B
Rationale:
Option B is correct. GnRH agonists such as leuprolide initially stimulate pituitary GnRH receptors, producing a transient surge in LH and testosterone — the "flare" — over the first one to two weeks before receptor downregulation produces sustained castrate testosterone. In a man with vertebral metastases, this testosterone surge can transiently stimulate tumor growth and precipitate serious complications including spinal cord compression. The standard of care is to administer a non-steroidal androgen receptor antagonist (e.g., bicalutamide) beginning before and continuing through the early weeks of GnRH agonist therapy to block the androgen receptor and protect against the clinical consequences of the flare until castrate testosterone is achieved. (A GnRH antagonist, which produces no flare, is an alternative strategy.)
Option A: Option A is incorrect; GnRH agonists do produce an initial testosterone surge, so leuprolide alone leaves the patient unprotected during the flare.
Option C: Option C is incorrect; the flare results from a pituitary-driven LH surge raising testicular testosterone, not adrenal androgen release, so corticosteroids do not address it.
Option D: Option D is incorrect; metastatic prostate cancer is an indication for androgen deprivation, not a contraindication; delaying definitive therapy for analgesics alone is inappropriate.
Option E: Option E is incorrect; giving testosterone to a man with metastatic prostate cancer would stimulate tumor growth and directly opposes the therapeutic goal of androgen deprivation.
5. A 54-year-old man is prescribed dutasteride 0.5 mg daily for BPH. During counseling he mentions that his 32-year-old wife is 10 weeks pregnant. Which of the following counseling points is most important to convey?
A) Dutasteride poses a risk only if directly ingested by the pregnant woman; ordinary household contact and intimate contact require no precautions.
B) The couple should avoid conception while he takes dutasteride, but once his wife is already pregnant there is no further fetal risk from his therapy.
C) Dutasteride is hazardous to a male fetus only during the third trimester, so no precautions are needed during the current first-trimester period.
D) His wife should stop her prenatal vitamins while he is on dutasteride because of a drug interaction that increases fetal exposure.
E) Because dutasteride can impair normal development of a male fetus's external genitalia by reducing DHT, his pregnant wife must not handle crushed or broken tablets, and — given dutasteride's long half-life and persistence in semen for up to 6 months after discontinuation — the couple should use a condom or avoid semen exposure during her pregnancy.
ANSWER: E
Rationale:
Option E is correct. 5 alpha-reductase inhibitors are contraindicated in pregnancy because DHT is required for normal virilization of the male fetal external genitalia; fetal exposure can produce ambiguous or undervirilized genitalia in a male fetus. Two exposure routes matter for a male partner's pregnant spouse: dermal absorption from handling crushed or broken tablets (intact coated tablets are safer), and exposure to semen, which carries measurable dutasteride. Dutasteride is distinguished by a long elimination half-life (~3 to 5 weeks) and persistence of measurable concentrations in semen for up to 6 months after discontinuation. Therefore the couple should avoid semen exposure (e.g., condom use) during her pregnancy, and she should not handle crushed or broken tablets.
Option A: Option A is incorrect; the risk is not limited to direct ingestion — dermal absorption from broken tablets and semen exposure are both relevant routes.
Option B: Option B is incorrect; an established pregnancy is precisely when fetal exposure is dangerous, and semen-borne dutasteride means risk continues during the pregnancy.
Option C: Option C is incorrect; male external genital virilization occurs during the first trimester, so first-trimester exposure is the period of greatest concern, not the third.
Option D: Option D is incorrect; there is no interaction requiring discontinuation of prenatal vitamins, and stopping them would be harmful; the genuine concern is fetal DHT reduction via dermal or semen exposure.
6. A 74-year-old man with metastatic castration-resistant prostate cancer has progressed clinically and biochemically on enzalutamide while maintained on a GnRH agonist. Circulating tumor cell testing is positive for AR-V7. Which of the following is the most appropriate next treatment?
A) Switch to apalutamide, a newer androgen receptor antagonist, which retains efficacy against AR-V7-positive disease because it binds the ligand-binding domain more tightly than enzalutamide.
B) Add high-dose exogenous testosterone to overwhelm the mutated receptor and restore hormone sensitivity.
C) Initiate taxane chemotherapy (docetaxel or cabazitaxel), because AR-V7 is a constitutively active androgen receptor splice variant lacking the ligand-binding domain that renders the tumor resistant to androgen receptor-directed agents, whereas taxanes act on microtubules independently of androgen receptor status.
D) Switch to abiraterone alone, since lowering androgen synthesis will control an AR-V7-driven tumor that no longer requires the ligand-binding domain.
E) Discontinue all systemic therapy and proceed directly to hospice, as no treatment retains activity once AR-V7 is detected.
ANSWER: C
Rationale:
Option C is correct. AR-V7 is a constitutively active, truncated androgen receptor splice variant that lacks the C-terminal ligand-binding domain (LBD). Because it signals without androgen and has no LBD, it is resistant to competitive androgen receptor antagonists (enzalutamide, apalutamide, darolutamide, bicalutamide), all of which act at the LBD, and it is not effectively controlled by abiraterone, which works by lowering androgen synthesis (depriving ligand from a receptor that no longer needs ligand). Taxane chemotherapy (docetaxel or cabazitaxel) acts on microtubules to disrupt mitotic and intracellular trafficking — a mechanism independent of the androgen receptor and its splice variants — and therefore retains activity in AR-V7-positive disease, making it the appropriate next therapy.
Option A: Option A is incorrect; apalutamide also binds the LBD, so it cannot block a receptor variant that lacks the LBD; it does not retain efficacy against AR-V7-positive disease.
Option B: Option B is incorrect; adding testosterone to metastatic prostate cancer would stimulate any androgen-responsive disease and is not a rational therapy for AR-V7-positive CRPC.
Option D: Option D is incorrect; abiraterone depletes androgen, which does not meaningfully suppress a ligand-independent, constitutively active AR-V7 receptor.
Option E: Option E is incorrect; AR-V7 positivity predicts resistance to AR-directed agents but not to taxanes, so effective systemic therapy remains available and proceeding directly to hospice is inappropriate.
7. A 49-year-old hypogonadal man receives a deep intramuscular injection of testosterone undecanoate 1,000 mg (in castor oil vehicle) in the clinic. Approximately 3 minutes after the injection he develops an acute cough, shortness of breath, chest tightness, and lightheadedness, and briefly feels he might faint. His symptoms begin to subside over the next 20 minutes with supportive observation. Which of the following best explains this event?
A) An IgE-mediated anaphylactic reaction to the testosterone molecule itself, requiring lifelong avoidance of all testosterone formulations.
B) Pulmonary oil microembolism (POME), a reaction to the oily castor oil vehicle entering the venous circulation through inadvertent intravascular injection or rapid vascular uptake, producing transient cough, dyspnea, chest tightness, and presyncope shortly after injection — which is why a 30-minute post-injection observation period is mandated for this formulation.
C) Acute testosterone toxicity from the supraphysiological dose causing immediate cardiac ischemia, requiring emergent cardiac catheterization.
D) A vasovagal reaction to the injection that is unrelated to the drug or vehicle and carries no specific monitoring requirement for this formulation.
E) An acute hemolytic reaction triggered by the testosterone ester, producing hypoxemia from red cell destruction.
ANSWER: B
Rationale:
Option B is correct. Testosterone undecanoate 1,000 mg intramuscular (Nebido) is administered in a large-volume castor oil vehicle and carries a recognized risk of pulmonary oil microembolism (POME). POME arises from inadvertent intravascular injection or rapid vascular uptake of the oily vehicle, which travels to the pulmonary circulation and produces a constellation of transient respiratory and vasomotor symptoms — cough, dyspnea, chest tightness, dizziness, and presyncope — that characteristically begin within minutes of injection and typically resolve over a short period with supportive care. Because of this risk (and the risk of anaphylaxis), a mandatory 30-minute post-injection observation period is required for this formulation. The timing (minutes after injection), the symptom pattern, and the formulation in this vignette are classic for POME.
Option A: Option A is incorrect; the presentation is not a classic IgE-mediated anaphylaxis to testosterone (no urticaria, angioedema, or hypotensive shock described), and lifelong avoidance of all testosterone formulations is not warranted — other formulations do not carry the POME risk of the large-volume oil depot.
Option C: Option C is incorrect; the self-limited respiratory and presyncopal symptoms are not acute coronary ischemia, and emergent catheterization is not indicated for this characteristic POME picture.
Option D: Option D is incorrect; while a vasovagal reaction can occur with injections, the specific respiratory symptoms tied to this oil-vehicle formulation reflect POME, and this formulation does carry a specific mandated observation requirement.
Option E: Option E is incorrect; testosterone esters do not cause acute hemolysis, and hemolysis is not the mechanism of these post-injection respiratory symptoms.
8. A 28-year-old transgender woman on feminizing therapy that includes spironolactone 200 mg daily and estradiol presents with generalized muscle weakness, fatigue, and palpitations. She was recently started on lisinopril for hypertension by another clinician and also takes a daily potassium-containing salt substitute. Her ECG shows peaked T waves. Which of the following is the most likely explanation for her presentation?
A) Hyperkalemia resulting from the additive potassium-retaining effects of spironolactone (a mineralocorticoid receptor antagonist), the ACE inhibitor lisinopril (which lowers aldosterone), and the potassium-containing salt substitute; the muscle weakness, palpitations, and peaked T waves are characteristic of elevated serum potassium.
B) Hypokalemia from spironolactone-induced renal potassium wasting, requiring urgent potassium repletion.
C) Estradiol-induced thromboembolism producing her symptoms, unrelated to any electrolyte disturbance.
D) Hypernatremia caused by the salt substitute, producing neuromuscular irritability and ECG changes.
E) Acute hypocalcemia from spironolactone's effect on calcium handling, accounting for the weakness and ECG findings.
ANSWER: A
Rationale:
Option A is correct. Spironolactone is a mineralocorticoid receptor antagonist that reduces renal potassium excretion and predisposes to hyperkalemia. This patient has three additive potassium-retaining or potassium-loading influences: spironolactone, the ACE inhibitor lisinopril (which lowers aldosterone and thereby further reduces potassium excretion), and a potassium-containing salt substitute (an exogenous potassium load). The clinical picture — generalized muscle weakness, palpitations, and peaked T waves on ECG — is characteristic of hyperkalemia, which can progress to dangerous arrhythmias. Management includes recognizing the additive contributions, checking serum potassium urgently, and removing the potassium load while treating the hyperkalemia.
Option B: Option B is incorrect; spironolactone is potassium-sparing and causes hyperkalemia, not hypokalemia; peaked T waves indicate high (not low) potassium.
Option C: Option C is incorrect; while estradiol increases thromboembolism risk, thromboembolism does not produce peaked T waves, and the combination of three potassium-retaining factors with classic hyperkalemic ECG changes points clearly to hyperkalemia.
Option D: Option D is incorrect; a potassium-containing salt substitute raises potassium, not sodium, and the ECG finding of peaked T waves is a hyperkalemia hallmark, not a hypernatremia sign.
Option E: Option E is incorrect; spironolactone does not characteristically cause acute hypocalcemia, and the peaked T waves are typical of hyperkalemia rather than hypocalcemia (which prolongs the QT interval).
9. A 30-year-old male competitive bodybuilder presents with right upper quadrant discomfort, pruritus, dark urine, and scleral icterus. He has been taking oral stanozolol for several months as part of a self-administered regimen. Laboratory testing shows a cholestatic pattern with markedly elevated bilirubin and a disproportionately modest transaminase elevation. Which of the following best explains his presentation?
A) Acute viral hepatitis unrelated to his anabolic steroid use, requiring only supportive care and no change to his stanozolol.
B) Aromatization of stanozolol to estrogenic metabolites causing estrogen-mediated cholestasis, which will resolve only with an aromatase inhibitor.
C) Rhabdomyolysis from intense training producing pigmenturia mistaken for cholestasis, with no hepatic involvement.
D) Cholestatic hepatotoxicity from the C17-alpha-alkylated oral anabolic steroid stanozolol; the 17-alpha-alkyl group impairs hepatic conjugation and biliary excretion, producing intrahepatic cholestasis (and, with prolonged use, peliosis hepatis and hepatic tumors), and management requires discontinuing the oral agent.
E) Gilbert syndrome unmasked by exercise, fully explaining the cholestatic laboratory pattern without any contribution from the steroid.
ANSWER: D
Rationale:
Option D is correct. Stanozolol is a C17-alpha-alkylated oral anabolic-androgenic steroid. The 17-alpha-alkyl group, which confers oral bioavailability by blocking first-pass hepatic oxidation at the 17-beta hydroxyl, also impairs the hepatocyte's normal conjugation and biliary excretion of the steroid, producing dose-dependent intrahepatic cholestasis; with prolonged high-dose use, C17-alpha-alkylated agents are additionally associated with peliosis hepatis and hepatocellular adenoma/carcinoma. This patient's cholestatic pattern (markedly elevated bilirubin with disproportionately modest transaminase elevation), pruritus, dark urine, and jaundice in the setting of oral stanozolol use is characteristic, and management requires discontinuing the offending oral agent.
Option A: Option A is incorrect; while viral hepatitis should be considered in the differential, the cholestatic pattern in a man using an oral 17-alpha-alkylated steroid points to drug-induced cholestasis, and continuing stanozolol would be inappropriate.
Option B: Option B is incorrect; the hepatotoxicity of 17-alpha-alkylated steroids arises from impaired conjugation and biliary excretion, not from aromatization to estrogenic metabolites; an aromatase inhibitor does not treat it.
Option C: Option C is incorrect; rhabdomyolysis produces myoglobinuria and elevated creatine kinase, not a cholestatic pattern with hyperbilirubinemia and jaundice.
Option E: Option E is incorrect; Gilbert syndrome causes mild unconjugated hyperbilirubinemia without a true cholestatic picture, pruritus, or dark urine, and does not account for this presentation in the setting of oral anabolic steroid use.
10. A 34-year-old man with a 7-year history of high-dose anabolic-androgenic steroid use for bodybuilding presents after an episode of exertional syncope. Echocardiography shows concentric left ventricular hypertrophy with reduced diastolic compliance, and his lipid panel reveals a markedly low HDL cholesterol. Coronary CT angiography shows premature coronary calcification. Which of the following best characterizes his cardiovascular risk?
A) His cardiac findings represent normal physiological athletic remodeling (eccentric hypertrophy with enhanced diastolic function) and carry no increased risk of arrhythmia or coronary events.
B) The low HDL cholesterol is protective against coronary disease, and the concentric hypertrophy is fully reversible within days of stopping anabolic steroids, so his cardiovascular risk is minimal.
C) His syncope is most likely vasovagal and unrelated to his anabolic steroid use or cardiac structure, requiring no further cardiac evaluation.
D) The coronary calcification reflects expected age-related atherosclerosis with no contribution from anabolic steroid use, and his lipid profile is unrelated to his steroid regimen.
E) Long-term anabolic-androgenic steroid use produces pathological concentric left ventricular hypertrophy with impaired diastolic function and arrhythmia predisposition, an atherogenic lipid profile (notably markedly reduced HDL cholesterol with variable LDL elevation), and accelerated premature coronary artery disease — a combination that markedly elevates his risk of malignant arrhythmia, sudden cardiac death, and coronary events, and his exertional syncope is a concerning warning sign warranting urgent cardiac evaluation.
ANSWER: E
Rationale:
Option E is correct. Cardiovascular toxicity is the leading cause of premature mortality in long-term anabolic-androgenic steroid (AAS) users, and this patient exhibits its hallmark features. AAS drive pathological concentric left ventricular hypertrophy (increased wall thickness with reduced or normal chamber volume) with impaired diastolic compliance and a predisposition to arrhythmia — distinct from the eccentric, function-preserving hypertrophy of physiological athletic remodeling. AAS also produce an atherogenic lipid profile, most characteristically a marked reduction in HDL cholesterol with variable LDL elevation, and accelerate coronary atherosclerosis, as evidenced here by premature coronary calcification in a young man. The combination substantially raises the risk of malignant arrhythmia, sudden cardiac death, and coronary events; exertional syncope in this context is an alarming symptom that warrants urgent cardiac evaluation.
Option A: Option A is incorrect; concentric hypertrophy with reduced diastolic compliance is pathological, not the eccentric, function-preserving remodeling of athletic training, and it carries real arrhythmic risk.
Option B: Option B is incorrect; low HDL is atherogenic (not protective), and AAS-associated structural cardiac changes and fibrosis are not reliably reversible within days; his risk is far from minimal.
Option C: Option C is incorrect; exertional syncope in a man with concentric LVH, impaired diastolic function, and premature coronary disease is an ominous finding that mandates evaluation, not dismissal as vasovagal.
Option D: Option D is incorrect; the coronary calcification and dyslipidemia in a 34-year-old are not simply age-related and unrelated to his regimen — AAS directly contribute to both the atherogenic lipid profile and accelerated coronary disease.
11. A 64-year-old man with hypogonadism and elevated cardiovascular risk has been on testosterone replacement therapy for 9 months. He presents with new-onset palpitations and is found to be in atrial fibrillation; he also reports a recent episode of pleuritic chest pain and dyspnea, and workup confirms a small pulmonary embolism. He has no other identifiable provoking factors. Which of the following best reflects the current understanding of testosterone therapy and these events?
A) Testosterone replacement therapy has been definitively shown to substantially increase the rate of major adverse cardiovascular events (myocardial infarction, stroke, cardiovascular death), so these arrhythmic and thrombotic events confirm an expected increase in that composite endpoint.
B) While large randomized data indicate testosterone replacement therapy is non-inferior to placebo for major adverse cardiovascular events (myocardial infarction, stroke, cardiovascular death) in men with elevated cardiovascular risk, the same evidence identified increased rates of atrial fibrillation and pulmonary embolism with testosterone; his new atrial fibrillation and pulmonary embolism are consistent with these recognized risks and warrant management of the arrhythmia and thromboembolism and reassessment of continued therapy.
C) Testosterone replacement therapy reduces the risk of both atrial fibrillation and venous thromboembolism, so these events must be entirely unrelated to his therapy and require no reconsideration of treatment.
D) Atrial fibrillation and pulmonary embolism are not associated with testosterone therapy under any circumstances, so testosterone can be confidently excluded as a contributing factor and continued without reassessment.
E) These events indicate that testosterone therapy is absolutely contraindicated in all men regardless of risk profile and that no man should ever receive testosterone replacement.
ANSWER: B
Rationale:
Option B is correct. Contemporary randomized evidence in hypogonadal men with elevated cardiovascular risk found that testosterone replacement therapy was non-inferior to placebo for the primary composite of major adverse cardiovascular events (non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death). Importantly, the same evidence identified increased rates of specific secondary events with testosterone — notably atrial fibrillation and pulmonary embolism (as well as acute kidney injury). This patient's new atrial fibrillation and confirmed pulmonary embolism, without other provoking factors, are consistent with these recognized risks; appropriate management includes treating the arrhythmia and the thromboembolism and reassessing whether to continue testosterone therapy. This question applies the clinical implications of the evidence rather than testing recall of a trial name.
Option A: Option A is incorrect; the major adverse cardiovascular event composite was non-inferior (not substantially increased), so these events do not confirm an expected increase in that endpoint; the relevant recognized signals are atrial fibrillation and pulmonary embolism, which are distinct from the composite.
Option C: Option C is incorrect; testosterone therapy does not reduce atrial fibrillation or venous thromboembolism risk — the evidence shows increased rates — so the events cannot be dismissed as unrelated.
Option D: Option D is incorrect; atrial fibrillation and pulmonary embolism are recognized associations with testosterone therapy, so testosterone should not be summarily excluded as a contributor, and reassessment is appropriate.
Option E: Option E is incorrect; the evidence does not render testosterone absolutely contraindicated for all men; it informs individualized risk-benefit assessment and monitoring, with specific contraindications (e.g., recent myocardial infarction or stroke, severe heart failure) rather than a universal prohibition.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.